Cyclerion Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
SIGNAT URES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned, thereunto duly authorized, on March 5, 2024.
| CYCLERION THERAPEUTICS, INC. | |
| By: | /s/ Regina Graul |
| Regina Graul | |
| President |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Regina Graul and Rhonda Chicko, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K of Cyclerion Therapeutics, Inc.,
and any or all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on March 5, 2024.
| Signature | Title |
|---|---|
| /s/ Regina Graul | |
| Regina Graul | President (Principal Executive Officer) |
| /s/ Rhonda Chicko | |
| Rhonda Chicko | Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
| /s/ Errol De Souza | |
| Errol De Souza | Director |
| /s/ Peter Hecht | |
| Peter Hecht | Director |
| /s/ Michael Higgins | |
| Michael Higgins | Director |
| /s/ Steven Hyman | |
| Steven Hyman | Director |
| /s/ Dina Katabi | |
| Dina Katabi | Director |
| /s/ Terrance McGuire | |
| Terrance McGuire | Director |
Index to Consolidated Financial Statements of Cyclerion Therapeutics, Inc.
| Page | |
| Report of Independent Registered Public Accounting Firm - PCAOB ID:42 | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-3 |
| Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2023 and 2022 | F-4 |
| Consolidated Statement of Stockholders’ Equity for the Years Ended December 31, 2023 and 2022 | F-5 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022 | F-6 |
| Notes to the Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.